Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
Outline of Final Research Achievements |
A novel Galectin-3 inhibitor significantly suppressed the proliferative and invasive potential of hepatocellular carcinoma and pancreatic cancer cell lines in a volume-dependent manner without toxicity to normal hepatocytes. In vivo studies, intraperitoneal daily administration of Galectin-3 inhibitor suppressed the growth of subcutaneous tumors in mice with pancreatic cancer and was well tolerated. CAGE analysis showed that Galectin-3 inhibitors act in the nucleus and inhibit elements involved in DNA replication and the cell cycle. In addition, a patient-derived xenograft model of tumor tissue transplantation was successfully established in patients with intraductal papillary mucinous carcinoma and metastatic liver carcinoma.
|